1. Home
  2. EDVA vs BDRX Comparison

EDVA vs BDRX Comparison

Compare EDVA & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EDVA

Endovia Health Sciences Inc. Common Stock

N/A

Current Price

$0.26

Market Cap

1.9M

ML Signal

N/A

Logo Biodexa Pharmaceuticals plc

BDRX

Biodexa Pharmaceuticals plc

HOLD

Current Price

$0.73

Market Cap

1.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDVA
BDRX
Founded
N/A
2000
Country
United Kingdom
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9M
1.6M
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
EDVA
BDRX
Price
$0.26
$0.73
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
236.1K
7.2M
Earning Date
N/A
09-12-2025
Dividend Yield
N/A
N/A
EPS Growth
32.30
N/A
EPS
N/A
N/A
Revenue
$73,066.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.60
52 Week High
$0.32
$11.88

Technical Indicators

Market Signals
Indicator
EDVA
BDRX
Relative Strength Index (RSI) 28.45 38.60
Support Level $0.23 $0.61
Resistance Level N/A $1.58
Average True Range (ATR) 0.03 0.18
MACD -0.00 0.03
Stochastic Oscillator 29.19 13.66

Price Performance

Historical Comparison
EDVA
BDRX

About EDVA Endovia Health Sciences Inc. Common Stock

Endovia Health Sciences Inc is building a diversified cannabinoid health sciences platform through pharmaceutical innovation, strategic partnerships and disciplined execution. Endovia acquires, develops and commercializes differentiated cannabinoid health technologies across pharmaceutical, veterinary and consumer wellness markets. Endovia's product begins with CannEpil, a cannabinoid pharmaceutical asset, and extends into veterinary development and consumer wellness as the pipeline expands.

About BDRX Biodexa Pharmaceuticals plc

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

Share on Social Networks: